HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
ASND
Ascendis Pharma A/S
Healthcare Biotechnology ADR · Denmark · Reports in eur
Market Cap: $14.01B
Market Cap
$14.01B
Enterprise Val
$14.61B
P/E Ratio
-52.42
P/B Ratio
-73.42
Trailing PEG (1Y)
5.24
As Of
Apr 23, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value-$191.2M
Gross Margin90.47%
Profit Margin90.47%
Return on Equity127.70%
Return on Assets-19.80%
Current Ratio1.04
Debt/Equity-6.93
LT Debt/Equity-6.93
Revenue Per Share4.76

Income Statement

Dec 31, 2025
Revenue$291.2M
Cost of Revenue$27.8M
Gross Profit$263.4M
R&D$91.9M
SG&A$159.8M
Operating Expenses$251.8M
Operating Income$11.6M
Interest Expense$72.9M
Tax Expense$8.1M
Net Income-$39.5M
EPS (Basic)$-0.64
EPS (Diluted)$-0.64
EBIT$41.5M
EBITDA$47.2M
Consolidated Income-$39.5M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$724.8M
Accounts Receivable$196.2M
Inventory$354.7M
Current Assets$1.30B
LT Investments$38.3M
Property, Plant & Equipment$172.3M
Intangibles$4.4M
Non-Current Assets$227.7M
Total Assets$1.53B
Accounts Payable$106.7M
Current Debt$0.00
Current Liabilities$1.26B
LT Debt$1.33B
Non-Current Liabilities$465.9M
Total Liabilities$1.72B
Total Debt$1.33B
Retained Earnings-$201.3M
Shareholder Equity-$191.6M
Shares Outstanding61,098,156

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow$86.4M
Investing Cash Flow-$4.0M
Financing Cash Flow$10.0M
CapEx-$4.0M
Free Cash Flow$82.4M
Depreciation & Amort.$5.7M
Stock-Based Comp$35.2M
Investment Activity$0.00
Debt Issued/Repaid-$8.0M
Equity Issued/Repaid$18.1M
Net Change in Cash$92.4M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h